These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27320565)

  • 1. Impact of Donor-Specific Antibodies on Graft Fibrosis After Pediatric Living Donor Liver Transplantation for Biliary Atresia.
    Ueno T; Zenitani M; Yamanaka H; Tanaka N; Uehara S; Tazuke Y; Bessho K; Okuyama H
    Transplant Proc; 2016 May; 48(4):1095-9. PubMed ID: 27320565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of serum autotoxin in regular follow up after pediatric living donor liver transplantation for biliary atresia.
    Ueno T; Takase K; Toyama C; Deguchi K; Masahata K; Nomura M; Watanabe M; Kamiyama M; Tazuke Y; Bessho K; Okuyama H
    J Pediatr Surg; 2022 Jul; 57(7):1215-1220. PubMed ID: 35396089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft fibrosis in patients with biliary atresia after pediatric living-related liver transplantation.
    Ueno T; Tanaka N; Ihara Y; Takama Y; Yamada H; Mushiake S; Fukuzawa M
    Pediatr Transplant; 2011 Aug; 15(5):470-5. PubMed ID: 21771230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts.
    Miyagawa-Hayashino A; Yoshizawa A; Uchida Y; Egawa H; Yurugi K; Masuda S; Minamiguchi S; Maekawa T; Uemoto S; Haga H
    Liver Transpl; 2012 Nov; 18(11):1333-42. PubMed ID: 22888064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Implications of Serum Mac-2 Binding Protein in Patients After Living Donor Liver Transplantation for Biliary Atresia.
    Ueno T; Takase K; Deguchi K; Nomura M; Watanabe M; Kamiyama M; Tazuke Y; Kimura T; Okuyama H
    Transplant Proc; 2024 Mar; 56(2):343-347. PubMed ID: 38360465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Living donor liver transplantation for post-Kasai biliary atresia: Analysis of pretransplant predictors of outcomes in infants.
    Kitajima T; Sakamoto S; Sasaki K; Uchida H; Narumoto S; Fukuda A; Teramukai S; Uemoto S; Kasahara M
    Liver Transpl; 2017 Sep; 23(9):1199-1209. PubMed ID: 28590589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Portal vein thrombosis in biliary atresia patients after living donor liver transplantation.
    Ou HY; Concejero AM; Huang TL; Chen TY; Tsang LL; Chen CL; Yu PC; Yu CY; Cheng YF
    Surgery; 2011 Jan; 149(1):40-7. PubMed ID: 20570300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of post-transplant donor-specific HLA antibody with liver graft fibrosis during long-term follow-up after pediatric liver transplantation.
    Tokodai K; Miyagi S; Nakanishi C; Hara Y; Nakanishi W; Miyazawa K; Shimizu K; Murakami K; Sasano H; Goto M; Unno M; Kamei T
    Pediatr Transplant; 2018 May; 22(3):e13169. PubMed ID: 29542229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Recipient Age at Liver Transplantation on Prevalence of Post-Transplant Donor-Specific HLA Antibody.
    Tokodai K; Miyagi S; Nakanishi C; Hara Y; Nakanishi W; Unno M; Kamei T
    Ann Transplant; 2017 Jun; 22():333-337. PubMed ID: 28572563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal.
    Ohe H; Uchida Y; Yoshizawa A; Hirao H; Taniguchi M; Maruya E; Yurugi K; Hishida R; Maekawa T; Uemoto S; Terasaki PI
    Transplantation; 2014 Nov; 98(10):1105-11. PubMed ID: 24914568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in living donor liver transplantation for biliary atresia and challenges faced: A thirty-year single institutional experience.
    Okamoto T; Okajima H; Ogawa E; Sonoda M; Uebayashi EY; Ito T; Seo S; Hata K; Masui T; Taura K; Uemoto S; Hatano E
    J Pediatr Surg; 2022 Nov; 57(11):649-655. PubMed ID: 35393118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and predictive value for graft fibrosis of the complement-binding capacity of donor-specific human leukocyte antigen antibodies after pediatric liver transplantation.
    Tokodai K; Miyagi S; Nakanishi W; Nishimura R; Fujio A; Goto M; Unno M; Kamei T
    Pediatr Transplant; 2020 Feb; 24(1):e13648. PubMed ID: 31885148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Living-donor liver transplantation at the University of Tokyo, 1996-2011: the impact of HLA matching and a positive crossmatch on long-term survival and tolerance.
    Waki K; Sugawara Y; Mizuta K; Fujita H; Kadowaki T; Kokudo N
    Clin Transpl; 2011; ():223-35. PubMed ID: 22755416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Living-donor liver transplantation for congenital biliary atresia with porto-pulmonary hypertension and moderate or severe pulmonary arterial hypertension: Kyoto University experience.
    Ogawa E; Hori T; Doi H; Segawa H; Uemoto S
    Clin Transplant; 2014 Sep; 28(9):1031-40. PubMed ID: 24986560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal grafts protect daughter recipients from acute cellular rejection after pediatric living donor liver transplantation for biliary atresia.
    Sanada Y; Kawano Y; Miki A; Aida J; Nakamura K; Shimomura N; Ishikawa N; Arai T; Hirata Y; Yamada N; Okada N; Wakiya T; Ihara Y; Urahashi T; Yasuda Y; Takubo K; Mizuta K
    Transpl Int; 2014 Apr; 27(4):383-90. PubMed ID: 24472036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of repeat Kasai hepatic portoenterostomy on pediatric live-donor liver graft for biliary atresia.
    Urahashi T; Ihara Y; Sanada Y; Wakiya T; Yamada N; Okada N; Mizuta K
    Exp Clin Transplant; 2013 Jun; 11(3):259-63. PubMed ID: 23530849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pre-Kasai procedure in living donor liver transplantation for children with biliary atresia.
    Wang Q; Yan LN; Zhang MM; Wang WT; Zhao JC; Pu CL; Li YC; Kang Q
    Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):47-53. PubMed ID: 23392798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deleterious impact of C3d-binding donor-specific anti-HLA antibodies after pediatric liver transplantation.
    Couchonnal E; Rivet C; Ducreux S; Dumortier J; Bosch A; Boillot O; Collardeau-Frachon S; Dubois R; Hervieu V; André P; Scoazec JY; Lachaux A; Dubois V; Guillaud O
    Transpl Immunol; 2017 Dec; 45():8-14. PubMed ID: 28782692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of living donor liver transplantation for post-Kasai biliary atresia in adults.
    Kyoden Y; Tamura S; Sugawara Y; Yamashiki N; Matsui Y; Togashi J; Kaneko J; Kokudo N; Makuuchi M
    Liver Transpl; 2008 Feb; 14(2):186-92. PubMed ID: 18236393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Clinical Relevance of De Novo Donor-Specific Antibodies After Pediatric Liver Transplantation.
    Grabhorn E; Binder TM; Obrecht D; Brinkert F; Lehnhardt A; Herden U; Peine S; Nashan B; Ganschow R; Briem-Richter A
    Transplantation; 2015 Sep; 99(9):1876-81. PubMed ID: 25706279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.